BE1002134A5 - Avipox virus recombinant. - Google Patents

Avipox virus recombinant. Download PDF

Info

Publication number
BE1002134A5
BE1002134A5 BE8800978A BE8800978A BE1002134A5 BE 1002134 A5 BE1002134 A5 BE 1002134A5 BE 8800978 A BE8800978 A BE 8800978A BE 8800978 A BE8800978 A BE 8800978A BE 1002134 A5 BE1002134 A5 BE 1002134A5
Authority
BE
Belgium
Prior art keywords
avipox
avipox virus
source
recombinant avipox
vertebrate
Prior art date
Application number
BE8800978A
Other languages
English (en)
French (fr)
Inventor
Enzo Paoletti
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE1002134(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Health Research Inc filed Critical Health Research Inc
Application granted granted Critical
Publication of BE1002134A5 publication Critical patent/BE1002134A5/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BE8800978A 1987-08-28 1988-08-29 Avipox virus recombinant. BE1002134A5 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9071187A 1987-08-28 1987-08-28
US11033587A 1987-10-20 1987-10-20
US18605488A 1988-04-25 1988-04-25
US23439088A 1988-08-23 1988-08-23

Publications (1)

Publication Number Publication Date
BE1002134A5 true BE1002134A5 (fr) 1990-07-24

Family

ID=27492413

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8800978A BE1002134A5 (fr) 1987-08-28 1988-08-29 Avipox virus recombinant.

Country Status (17)

Country Link
JP (3) JP3348156B2 (enrdf_load_stackoverflow)
KR (1) KR970011149B1 (enrdf_load_stackoverflow)
AR (1) AR241939A1 (enrdf_load_stackoverflow)
AT (1) AT408549B (enrdf_load_stackoverflow)
AU (2) AU2427588A (enrdf_load_stackoverflow)
BE (1) BE1002134A5 (enrdf_load_stackoverflow)
CH (2) CH679933A5 (enrdf_load_stackoverflow)
DE (4) DE10399032I1 (enrdf_load_stackoverflow)
DK (1) DK175904B1 (enrdf_load_stackoverflow)
FR (1) FR2621487B1 (enrdf_load_stackoverflow)
GB (1) GB2217718B (enrdf_load_stackoverflow)
IL (1) IL87581A0 (enrdf_load_stackoverflow)
IT (1) IT1229484B (enrdf_load_stackoverflow)
LU (2) LU90951I2 (enrdf_load_stackoverflow)
NL (4) NL195051C (enrdf_load_stackoverflow)
NZ (1) NZ225970A (enrdf_load_stackoverflow)
WO (1) WO1989003429A1 (enrdf_load_stackoverflow)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5286639A (en) * 1987-09-16 1994-02-15 Nippon Zeon Co., Ltd. Recombinant avipoxvirus
DE3813093A1 (de) * 1988-04-19 1989-11-09 Immuno Ag Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
DE68912441T2 (de) * 1988-06-24 1994-05-11 British Tech Group Nichtessentielle Geflügelpockenvirus-Regionen.
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) * 1988-10-21 1990-04-21 Matthew M. Binns Fowlpox virus promoter
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) * 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5503834A (en) * 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
IE71643B1 (en) * 1990-11-20 1997-02-26 Virogenetics Corp A recombinant poxviral vaccine for canine distemper
US5338679A (en) * 1991-01-08 1994-08-16 Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5756101A (en) * 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5766597A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
EP0575544A4 (en) * 1991-03-20 1997-05-21 Virogenetics Corp Malaria recombinant poxvirus vaccine
DE69233080T2 (de) * 1991-06-14 2004-04-15 Connaught Technology Corp., Greenville Rekombinanter hiv-spezifischer impfstoff aus poxviru
EP0597016A4 (en) * 1991-07-26 1996-04-24 Virogenetics Corp Infectious bursal disease virus recombinant poxvirus vaccine.
DK0538496T3 (da) * 1991-08-26 2004-02-23 Baxter Healthcare Sa Rekombinant fjerkrækoppevirus med intakt FPV tk-gen
US5443831A (en) * 1991-10-29 1995-08-22 University Of Delaware Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6127163A (en) * 1992-01-13 2000-10-03 Syntro Corporation Recombinant swinepox virus
US5869312A (en) * 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6251403B1 (en) 1992-01-13 2001-06-26 Syntro Corporation Recombinant swinepox virus
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US6497882B1 (en) 1992-01-13 2002-12-24 Syntro Corporation Recombinant swinepox virus
US6328975B1 (en) 1992-01-13 2001-12-11 Syntro Corporation Recombinant swinepox virus
AU680609B2 (en) * 1992-01-13 1997-08-07 Virogenetics Corporation Marek's disease virus recombinant poxvirus vaccine
AU5138293A (en) * 1992-09-21 1994-04-12 Chiron Viagene, Inc. Recombinant retroviral vector against felv and/or fiv
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
CA2156423A1 (en) * 1993-02-26 1994-09-01 Mark D. Cochran Recombinant fowlpox viruses and uses thereof
AU727278B2 (en) * 1993-02-26 2000-12-07 Syntro Corporation Recombinant fowlpox viruses and uses thereof II
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
WO1999007869A1 (en) * 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (ja) 1997-12-01 1999-06-22 Lintec Corp チップ体搬送用カバーテープおよび封止構造体
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
AU5771500A (en) 1999-06-28 2001-01-31 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
KR100848973B1 (ko) 2000-02-23 2008-07-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
AU2002305914A1 (en) 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
ATE318321T1 (de) * 2001-03-08 2006-03-15 Akzo Nobel Nv Leporipox-basierende vektorvakzine
JP4499311B2 (ja) * 2001-04-27 2010-07-07 シャープ株式会社 放送受信端末
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
CA2634992C (en) 2001-07-05 2012-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP2292772A1 (en) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
EP1589934B1 (en) 2003-01-06 2015-09-23 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2005007808A2 (en) 2003-05-15 2005-01-27 Chiron Corporation Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
RU2402347C2 (ru) 2004-09-22 2010-10-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
EP2441846A3 (en) 2006-01-09 2012-07-25 The Regents Of the University of California Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
US7842299B2 (en) 2006-03-14 2010-11-30 Oregon Health & Science University Methods for producing an immune response to tuberculosis
EP2918598B1 (en) 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
EP2215231A4 (en) 2007-10-15 2010-12-01 Univ Queensland EXPRESSION SYSTEM FOR MODULATING AN IMMUNE RESPONSE
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US8425922B2 (en) 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
CN102713629B (zh) 2009-11-20 2016-02-24 俄勒冈健康科学大学 用于检测结核分枝杆菌感染的方法
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
MX2013013627A (es) 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
BR112013032410A2 (pt) 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
CN115715797A (zh) 2013-04-17 2023-02-28 建新公司 用于治疗和预防黄斑变性的组合物和方法
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
MX2016010215A (es) 2014-02-06 2016-11-15 Genzyme Corp Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
JP7095990B2 (ja) 2014-09-18 2022-07-05 シーダーズ－サイナイ メディカル センター 線維症を治療するための組成物及び方法
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
EP3283529B1 (en) 2015-04-17 2023-06-07 The General Hospital Corporation Agents, systems and methods for treating cancer
EP4194001A1 (en) 2015-04-22 2023-06-14 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes and obesity
EP4276106A3 (en) 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3313863B1 (en) 2015-06-29 2020-12-23 The Board of Trustees of the Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
KR20180083437A (ko) 2015-12-09 2018-07-20 애드메더스 백신스 피티와이 리미티드 치료를 위한 면역조절용 조성물
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
US10917454B1 (en) 2019-08-01 2021-02-09 Rohde & Schwarz Gmbh & Co. Kg System and method for ATC voice quality assurance
US20250011787A1 (en) 2021-10-21 2025-01-09 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Retroelement-generated transcription factor decoys
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
EP4499849A1 (en) 2022-03-25 2025-02-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183589A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Rt-dna fidelity and retron genome editing
EP4499839A1 (en) 2022-03-25 2025-02-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Methods of assessing engineered retron activity, and uses thereof
CN120344660A (zh) 2022-07-18 2025-07-18 雷纳嘉德医疗管理公司 基因编辑组分、系统和使用方法
WO2024044673A1 (en) 2022-08-24 2024-02-29 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024233791A1 (en) 2023-05-11 2024-11-14 Seelos Therapeutics, Inc. Methods of treating neurodegenerative disorders
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052002A2 (en) * 1980-11-10 1982-05-19 G.D. Searle & Co. Plasmid vectors, production and use thereof
EP0162757A1 (fr) * 1984-04-25 1985-11-27 Transgene S.A. Vaccin contre la rage et procédé pour sa préparation
WO1986005806A1 (en) * 1985-03-29 1986-10-09 National Research Development Corporation Infectious bronchitis virus spike protein
EP0216564A2 (en) * 1985-09-09 1987-04-01 Cetus Corporation Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
EP0227414A2 (en) * 1985-12-18 1987-07-01 Btg International Limited Newcastle disease virus gene clones
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0284416A1 (en) * 1987-03-27 1988-09-28 Nippon Zeon Co., Ltd. Recombinant avipoxyvirus
EP0314569A1 (fr) * 1987-10-29 1989-05-03 Transgene S.A. Virus du fowlpox recombinant, vecteurs d'expression de protéines héterologues et vaccins pour la volaille dérivés de ce virus
WO1989003879A1 (en) * 1987-10-23 1989-05-05 National Research Development Corporation Fowlpox virus promoters

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
JPH0795954B2 (ja) * 1982-11-30 1995-10-18 アメリカ合衆国 外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
WO1986000528A1 (en) * 1984-07-05 1986-01-30 Genex Corporation Cloned gene and method for making and using the same
DD235669A1 (de) * 1985-03-26 1986-05-14 Akad Wissenschaften Ddr Verfahren zur herstellung eines blv-kodierten huellproteins
AU6170486A (en) * 1985-08-23 1987-02-26 Advanced Genetics Research Institute Defective viral vaccines
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
AU8075787A (en) * 1986-09-22 1988-04-07 Australian National University, The Recombinant poxviruses
EP0261940A3 (en) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies vaccines and dna vectors for recombination with pox viruses
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
DE68912441T2 (de) * 1988-06-24 1994-05-11 British Tech Group Nichtessentielle Geflügelpockenvirus-Regionen.
NL9020389A (nl) * 1989-03-08 1991-12-02 Health Research Inc Systeem voor het in de gastheer selecteren van recombinant-pokkenvirussen.
ATE194657T1 (de) * 1990-09-25 2000-07-15 Cantab Pharma Res Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052002A2 (en) * 1980-11-10 1982-05-19 G.D. Searle & Co. Plasmid vectors, production and use thereof
EP0162757A1 (fr) * 1984-04-25 1985-11-27 Transgene S.A. Vaccin contre la rage et procédé pour sa préparation
WO1986005806A1 (en) * 1985-03-29 1986-10-09 National Research Development Corporation Infectious bronchitis virus spike protein
EP0216564A2 (en) * 1985-09-09 1987-04-01 Cetus Corporation Infectious recombinant virus, vaccines containing said virus for feline leukemia, and methods for the production thereof
EP0227414A2 (en) * 1985-12-18 1987-07-01 Btg International Limited Newcastle disease virus gene clones
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0284416A1 (en) * 1987-03-27 1988-09-28 Nippon Zeon Co., Ltd. Recombinant avipoxyvirus
WO1989003879A1 (en) * 1987-10-23 1989-05-05 National Research Development Corporation Fowlpox virus promoters
EP0314569A1 (fr) * 1987-10-29 1989-05-03 Transgene S.A. Virus du fowlpox recombinant, vecteurs d'expression de protéines héterologues et vaccins pour la volaille dérivés de ce virus

Also Published As

Publication number Publication date
WO1989003429A1 (en) 1989-04-20
LU90951I2 (fr) 2003-01-15
AU2427588A (en) 1989-05-02
DK203689A (da) 1989-06-27
IT1229484B (it) 1991-09-03
NL8820679A (nl) 1989-07-03
AR241939A1 (es) 1993-01-29
DK203689D0 (da) 1989-04-27
DE10299049I1 (de) 2004-07-01
NL300138I1 (nl) 2004-02-02
FR2621487A1 (fr) 1989-04-14
AU1628895A (en) 1995-08-17
IL87581A0 (en) 1989-01-31
NL195051C (nl) 2003-07-01
KR970011149B1 (ko) 1997-07-07
JP2002348255A (ja) 2002-12-04
NL300130I2 (nl) 2005-11-01
GB8908921D0 (en) 1989-08-02
DE3890874C2 (de) 2003-03-13
NL300130I1 (nl) 2003-09-01
CH679933A5 (enrdf_load_stackoverflow) 1992-05-15
NZ225970A (en) 1991-01-29
DE10399032I1 (de) 2004-01-29
DE3890874C5 (de) 2005-10-20
JP3826055B2 (ja) 2006-09-27
JPH02500879A (ja) 1990-03-29
LU91039I2 (fr) 2003-11-05
CH679934A5 (enrdf_load_stackoverflow) 1992-05-15
NL300139I1 (nl) 2004-02-02
GB2217718B (en) 1992-05-20
DK175904B1 (da) 2005-06-06
AT408549B (de) 2001-12-27
AU690210B2 (en) 1998-04-23
JP2002186494A (ja) 2002-07-02
KR890701757A (ko) 1989-12-21
JP3348156B2 (ja) 2002-11-20
ATA900788A (de) 1995-05-15
DE10399031I1 (de) 2004-01-29
FR2621487B1 (fr) 1991-10-18
NL300138I2 (nl) 2004-03-01
GB2217718A (en) 1989-11-01
IT8821772A0 (it) 1988-08-29

Similar Documents

Publication Publication Date Title
BE1002134A5 (fr) Avipox virus recombinant.
DK0713495T3 (da) Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner
AR248044A1 (es) Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.
IT1278077B1 (it) Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
HUT73384A (en) Methods of typing hepatitis c virus and reagents for use therein
EA200000196A1 (ru) Универсальная плазма крови
FR2711670B1 (fr) Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
PT733069E (pt) Antigenios ctla-8 de primata purificados e reagentes relacionados
HUP9900929A2 (hu) Hepatitisz C-ben szenvedő betegek ismételt kezelési eljárásai konszenzus interferonnal
UA40572C2 (uk) Поліпептид, що містить укорочену послідовність вірусу гепатиту с, ізольований епітоп, реагент для імуноаналізу на вірус гепатиту с (варіанти), спосіб виявлення наявності антитіл (варіанти)
DK368588D0 (da) Bindingsmolekyler med en enkelt plypeptidkaede
DK108589D0 (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer
DK648689A (da) Non-a, non-b-hepatitisvirusgenom rna, dets cdna samt dets virusantigenprotein
CA2050304A1 (fr) Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
GB8601680D0 (en) Modification of plant viruses
EP0593290A3 (en) Core antigen protein of the hepatitis C virus, as well as diagnostic procedure and set of reagents.
DE69433400D1 (de) Neue proteine von parasitischen würmern
EP1013757A3 (en) Attenuated forms of bovine viral diarrhea virus
TR199501718A2 (tr) Papaya ringspot virüsü proteaz geni.
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
ATE162553T1 (de) Monoklonale antikörper gegen hepatitis-c-virus
RU96103965A (ru) Устройство для очистки скважин методом имплозии
PT728015E (pt) Antigenes polipeptidicos combinatoriais
ES2069298T3 (es) Secuencias no-a no-b.
DE3580482D1 (de) Monoklonale antikoerper und immunisierung damit.

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: *HEALTH RESEARCH INC.

Effective date: 20080829

CCRE Expiry of a supplementary protection certificate

Owner name: *HEALTH RESEARCH INC.

Free format text: PRODUCT NAME: VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/KENTUCKY/94 - VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/NEWMARKET/2/93 - ANATOXINE CLOSTRIDIUM TETANI; REGISTRATION NO/DATE: EU/2/03/038/00 20030307

Spc suppl protection certif: 2003C/022

Filing date: 20030901

Expiry date: 20080829

Extension date: 20130829

Effective date: 20130829

Free format text: product name: RCP FELV.; registration no/date: EU/2/02/031/001 20020311

Spc suppl protection certif: 2002C/024

Filing date: 20020904

Expiry date: 20080829

Extension date: 20130829

Effective date: 20080829

Free format text: product name: VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/KENTUCKY/94 - VIRUS CANARYPOX RECOMBINE GRIPPE A/EQUI-2/NEWMARKET/2/93; registration no/date: EU/2/03/037/001 20030307

Spc suppl protection certif: 2003C/021

Filing date: 20030901

Expiry date: 20080829

Extension date: 20130829

Effective date: 20080829